Drug intelligence / Profile preview

AB200

Development stage: Preclinical
Lead developer: Aromics
Modality: Small Molecules

Overview

AB200 is a preclinical small molecule antiviral candidate being developed by Aromics in collaboration with AESIS Therapeutics and Acceleration Biopharmaceuticals. The drug is targeted toward the treatment of Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), and HCV/HIV co-infections. AB200 has demonstrated in vitro proof of concept (PoC) as a novel antiviral agent. While specific mechanistic details regarding its biological target have not been publicly disclosed, it is part of Aromics' broader portfolio which often focuses on small molecules that modulate viral or disease-related RNA functions.

Beyond the preview

Go deeper on AB200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AB200.

Explore the full profile